ClinicalTrials.gg
CompletedNCT01618448Updated Jun 2, 2015

Efficacy and Safety of Tolvaptan in the Treatment of Cardiac-Induced Edema in Patients With Heart Failure

A Phase 3 interventional study of Tolvaptan and Placebo in Cardiac-induced Edema, sponsored by Taiwan Otsuka Pharm. Co., Ltd. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2015-06-02.

Sponsored by Taiwan Otsuka Pharm. Co., Ltd (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
20 Years to 85 Years
Sex
All
01

Study summary

A Multicenter, Double-blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tolvaptan in the Treatment of Cardiac-Induced Edema in Patients with Heart Failure

Read the detailed description

Interventional, phase III, 2-arm parallel group, placebo-controlled, multicenter, randomized 1:1, double-blind study, comparing Tolvaptan and placebo in hospitalized HF patients with signs or symptoms of congestion at the time of randomization in spite of standard therapy.This study intends to demonstrate that a repeated 4-day treatment with Tolvaptan in addition to standard of care (SOC) is superior to SOC alone for the treatment of clinical relevant cardiac-induced volume retention parameters in patients hospitalized for worsening HF initially treated with conventional therapy including diuretics.

02

Conditions studied

  • Cardiac-induced Edema
03

In context

Lead sponsor

Taiwan Otsuka Pharm. Co., Ltd is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with history of chronic HF hospitalized primarily for worsening HF with signs or symptoms of volume congestion in spite of standard therapy 3. Patient should have HF symptoms at rest or minimal exertion and signs of congestion (lower limb edema, jugular venous distention, or pulmonary congestion due to extracellular volume expansion) at time of randomization c. Anti-aldosterone drugs: Spironolactone, Triamterene 4. Patients undergoing any of the following diuretic therapies:
  • A loop diuretic at a daily dosage equivalent to 40 mg or more of furosemide
  • Concomitant administration of a loop diuretic and a thiazide diuretic (at any doses)
  • Concomitant administration of a loop diuretic and an anti-aldosterone drug (at any doses)

Note: The allowable types and dosages of the concomitantly administered diuretics are specified as follows:

  1. Loop diuretics equivalent to 40 mg of furosemide:

    Bumetanide: 1 mg, Piretanide: 6 mg, Azosemide: 60 mg, Torasemide: 8 mg

  2. Thiazide diuretics: Hydrochlorothiazide, Trichloromethiazide, Benzyl hydrochlorothiazide, Chlortalidone, Mefruside 5. Patients who had been taking an orally administered diuretic without any change in dose or mode of administration during Observation period 6. Patients whose body weight variation was within 1.0 kg during the 2 days prior start of treatment 7. Patients able to accomplish with study procedures from Screening period to Post-study follow-up 8. Patients capable of giving to participate in the study of their own free will.

Exclusion criteria

Exclusion Criteria:

  1. Cardiac surgery within 60 days of enrollment
  2. Patients with an assisted cardiac mechanical device
  3. Patients receiving CRT (Cardiac Resynchronization Therapy) within 60 days of enrollment.
  4. Patients with active or significant complications or symptoms as follow:

    • Suspected decrease in circulatory blood flow
    • end-stage HF (patients considered to require mechanical circulatory support, continuous intravenous positive inotropic therapy, referral of cardiac transplantation, or hospice care)
    • Cardiac valvular disease with significant heart valve stenosis
    • Sustained ventricular tachycardia or ventricular fibrillation within 30 days prior to screening examination
    • Acute myocardial infarction within 30 days prior to screening examination
    • Cerebrovascular disorders within 6 months prior to screening examination (other than asymptomatic cerebral infarction)
    • Patients with a definite diagnosis of active myocarditis or amyloid cardiomyopathy
    • Poorly controlled Diabetes Mellitus (HbAlc 10%)
    • Anuria (urinary output less than 100 ml per day)
    • History of Hyperthyroidism
    • Urination impaired due to urinary tract stricture, urinary calculus, tumor in urinary tract, or other cause
    • Hemofiltration or dialysis
    • Patients unable to sense thirst, inappropriately respond to thirst or those who have impaired oral fluid intake.
  5. Patients with a history of or idiosyncratic reaction to benzazepine derivatives such as mozavaptan hydrochloride or benazepril hydrochloride
  6. Patients who are severely obese ( exceeding 35 kg/m2)
  7. Patients with systolic blood pressure in the decubitus position below 90 mmHg
  8. Patients with any of following abnormal laboratory values:

    Total exceeding 3.0 mg/dL, of less than 9 g/dL, serum creatinine exceeding 3.0 mg/dL, serum sodium exceeding 147 mEq/L, or serum potassium exceeding 5.5 mEq/L

  9. Female patients who are pregnant, possibly pregnant, or lactating, or who plan to become pregnant
  10. Patients who received any drug other than Tolvaptan within 30 days prior to the screening examination
  11. Patients with general physical conditions, which may confound the results of the study, pose additional risk or preclude evaluation and assessments in this study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Placebo

    Placebo once daily

    Drug: Placebo

  • Experimental
    Tolvaptan

    Tolvaptan 15mg once daily

    Drug: Tolvaptan

Interventions

  • Tolvaptan 15mg once daily

    Also known as: Samsca

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change in body weight at 4-day of treatment.

    Time frame: baseline and 4-day of treatment

Secondary outcomes

  1. Change in Intake/Output Balance at 4-day of Treatment

    Time frame: baseline and 4-day of treatment

  2. Change in Serum Sodium and Potassium Concentration at 4-day of treatment

    Time frame: baseline and 4-day of treatment

  3. Treatment Failure at 4-day of Treatment

    Time frame: baseline and 4-day of treatment

  4. Changes in Physician-assessed Signs and Symptoms of Heart Failure at 4-day of Treatment

    Time frame: baseline and 4-day of treatment

  5. Changes in Patient Self-assessed Global Clinical Status at 4-day of Treatment

    Time frame: baseline and 4-day of treatment

  6. Changes in Patient Self-assessed Dyspnea Status at 4-day of Treatment

    Time frame: baseline and 4-day of treatment

  7. All-cause Mortality during the Study Period

    Total timeframe expected average of 37 days for each participant

    Time frame: Duration of hospital stay for 4 days, post-study follow up visit for 2 times

07

Study locations

1 site
  • National Taiwan University Hospita
    Taipei, Taiwan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of May 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2012
First posted
Jun 13, 2012
Start
Jul 2012
Primary completionActual
May 2014
CompletionActual
Dec 2014
Last update
Jun 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01618448
Responsible party
Sponsor
First posted
Jun 13, 2012
Start date
Jul 2012
Primary completion
May 2014
Completion
Dec 2014
Last update
Jun 2, 2015

Study contacts

Chuen-Den Tseng
principal investigator · National Taiwan University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion